Global Health Limited reported a 26.5% year-on-year revenue increase to ₹1,304 crore in Q1 FY27. The company's Noida hospital significantly cut its EBITDA loss to ₹5 crore, signaling improved operational efficiency. Investors are now tracking the company's ability to maintain margin targets as its 3,350-bed expansion pipeline continues to mature.
Global Health Limited, which operates the Medanta brand, has reported a strong start to fiscal year 2027. The company’s revenue for the first quarter reached ₹1,304 crore, marking a 26.5% increase compared to the same period last year. This performance was driven by a 21% rise in occupied bed days and a 5.5% improvement in Average Revenue Per Occupied Bed, which hit ₹70,244. While overall occupancy stood at 66%, the figure reflects the ongoing process of scaling up newer facilities.
Noida Hospital Performance and Expansion
A critical highlight of the quarterly results is the performance of the Noida hospital, which has been a major point of interest for investors tracking the company's capital allocation. The facility reported an EBITDA loss of ₹5 crore for the quarter, a sharp improvement from the ₹23.6-crore loss recorded in the final quarter of the previous fiscal year. With the addition of 51 beds during the period, the Noida unit now operates with a total capacity of 433 beds. The company confirmed that it has successfully secured key empanelment agreements with public sector undertakings, corporate entities, and insurance providers, which is expected to support the facility as it moves toward operational breakeven.
Margin Outlook and Future Growth
Looking ahead, Global Health is focused on managing its 3,350-bed expansion pipeline. The management aims to see consolidated EBITDA margins stabilize in the 25-26% range as these newly commissioned assets reach higher capacity utilization. The company’s strategy involves prioritizing high-acuity care, such as robotic surgeries, oncology, and organ transplants, to drive profitability. Furthermore, the company anticipates that its growing international patient base will provide a boost to revenue per bed, primarily through a more specialized case mix rather than sharp increases in service charges.
Investors may continue to track the pace of capacity utilization at the Noida facility and the broader progress of the 3,350-bed pipeline. The speed at which these new beds contribute to the bottom line remains a key monitorable, as higher fixed costs from expansion can often place pressure on margins until the facilities reach their target occupancy levels.